Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
Ryo Shinnakasu(The University of Osaka), Tomohiro Kurosaki(Osaka International University), Yoshimasa Takahashi(Hokkaido Pharmaceutical University), Po-Hung Wang(Institute of Physics, Academia Sinica), Takeshi Inoue(Tokyo Medical University), Masaharu Shinkai(New Tokyo Hospital), Yu Adachi(National Institute of Infectious Diseases), Kazuo Yamashita, Shuhei Sakakibara(The University of Osaka), Nicolas Sax, Saya Moriyama(Cornell University), Chikako Ono(The University of Osaka), Noritaka Hashii(National Institute of Health Sciences), Atsushi Yamanaka(The University of Osaka), Takashi Sato(New Tokyo Hospital), Yoshiharu Matsuura(Department of Virology), Taishi Onodera(National Institute of Infectious Diseases), Ryosuke Suzuki(National Institute of Infectious Diseases), Hiromi Yamamoto
Cited by 34
Related Papers
β <sub>2</sub> -adrenergic receptor–mediated negative regulation of group 2 innate lymphoid cell responses
|Science|2018|355
Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP
|Biochemical and Biophysical Research Communications|2013|330